Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

Rhea-AI Summary

Anbio Biotechnology announces its participation in three major international exhibitions in May 2025: EuroMedLab (Brussels), AVA Conference (Sydney), and ACMTT (Bangkok). The company will showcase its comprehensive diagnostic portfolio including:

• Fluorescence Immunoassay Systems supporting 90 test items
• Dry Chemistry Analyzers for point-of-care biochemical testing
• Rapid Test Kits for on-site diagnostics
• Molecular Diagnostic System featuring LAMP-based technology
• Veterinary Diagnostics Suite for companion animal health

With product registrations in over 100 countries, Anbio is actively seeking distribution partners, research collaborators, and strategic investors to expand its global presence in both human and animal healthcare diagnostics.

News Market Reaction – NNNN

-0.85%

1 alert

-0.85% News Effect

On the day this news was published, NNNN declined 0.85%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration

BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok. These events reflect Anbio’s strategic commitment to expanding its global footprint across human and animal healthcare, building new partnerships, and sharing its vision for accessible, high-performance diagnostics.

As healthcare systems around the world seek faster, more accurate, and decentralized testing solutions, Anbio is well-positioned to meet this demand through a diversified portfolio and expanding global network.

“These exhibitions are not just product showcases—they represent Anbio’s mission to reshape diagnostics through collaboration, innovation, and accessibility,” said Michael Lau, CEO of Anbio Biotechnology. “We look forward to connecting with partners and professionals who share our vision of smarter, more inclusive healthcare.”

At all three exhibitions, Anbio will feature its comprehensive diagnostic portfolio designed to meet the needs of both clinical and veterinary professionals. Key solutions include:

• Fluorescence Immunoassay (FIA) Systems: Supports 90 test items, offering rapid and quantitative detection across a broad range of clinical areas—including cardiac markers, hormones, infectious diseases, inflammation, tumor markers and others.
  
  
• Dry Chemistry Analyzers: Compact and user-friendly systems designed for essential biochemical testing at the point of care. Utilizing independent test strip-based reagents, offers a simpler, maintenance-free testing experience—ideal for decentralized settings such as community clinics, mobile units, and veterinary practices.
  
  
• Rapid Test Kits: Lateral flow and immunoassay-based kits for on-site diagnostics.
  
  
• Molecular Diagnostic System: Offers a versatile molecular diagnostics portfolio, including LAMP-based Rapid Mdx System, and real-time RT-PCR reagents. With room temperature-stable reagents and streamlined protocols, these solutions enable faster, more accessible nucleic acid detection.
  
  
• Veterinary Diagnostics Suite: Provides a comprehensive diagnostic solution for veterinarians, integrating immunoassays, biochemical testing, and molecular diagnostics. This all-in-one approach supports accurate, efficient, and on-site decision-making for a wide range of companion animal health needs.
  

These innovations are built on a shared foundation of accuracy, speed, and usability, enabling deployment in hospitals, labs, mobile units, veterinary clinics, and remote field settings.

Global Vision, Local Action
With product registrations in over 100 countries and a growing network of international partners, Anbio continues to pursue a global strategy of innovation, collaboration, and commercialization. Its participation in EuroMedLab, AVA, and ACMTT underscores a commitment to engaging with local markets while driving global standards.

As part of this initiative, Anbio is actively seeking distribution partners, research collaborators, and strategic investors to expand diagnostic access and co-develop market-specific solutions.

About Anbio Biotechnology
Anbio Biotechnology is a globally oriented IVD company focused on empowering healthcare professionals through innovative diagnostic solutions. Its portfolio spans immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, and rapid testing. With strong R&D capabilities and a presence in over 100 countries, Anbio is dedicated to building a healthier world through diagnostics that are fast, accurate, and accessible to all.

For more information about the Anbio Biotechnology, follow us on social media for the latest news and updates.

Contact:
jocelyn@anbio.com
Jocelyn Chow

FAQ

What products will Anbio Biotechnology showcase at the May 2025 exhibitions?

Anbio will showcase FIA Systems with 90 test items, Dry Chemistry Analyzers, Rapid Test Kits, Molecular Diagnostic System with LAMP technology, and a Veterinary Diagnostics Suite.

Which international exhibitions will Anbio Biotechnology attend in May 2025?

Anbio will attend EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok.

How many countries have approved Anbio Biotechnology's products?

Anbio Biotechnology has product registrations in over 100 countries globally.

What type of partners is Anbio Biotechnology currently seeking?

Anbio is actively seeking distribution partners, research collaborators, and strategic investors to expand diagnostic access and develop market-specific solutions.